Business Wire

The Princess Alexandra Hospital NHS Trust Enhances its Cybersecurity with Armis

19.2.2025 09:00:00 CET | Business Wire | Press release

Share

Healthcare delivery organization effectively balances innovation and security to drive improved quality of care

Armis, the cyber exposure management & security company, today announced that it is enabling The Princess Alexandra Hospital NHS Trust (PAHT) to protect its entire attack surface and manage cyber risk exposure in real time, underpinning the delivery of world-class patient care.

PAHT leverages AI-powered Armis CentrixTM, the Armis Cyber Exposure Management Platform, to proactively identify and mitigate all cyber asset risks, remediate security findings and vulnerabilities and protect the entire attack surface. Armis CentrixTM for Medical Device Security is a specialized solution engineered to protect healthcare institutions from the growing threat landscape targeting medical devices.

“Putting quality first is the Trust’s approach to everything we do as we strive for excellence, and cybersecurity is no exception,” said Jeffrey Wood, Deputy Director of ICT at PAHT. “Armis has supported us in mitigating risk to our environment, including the large number of physical and virtual assets on-site, legacy technologies needing to be segregated from the corporate network and connected assets that were actively communicating externally. We have identified and strengthened our cyber security approach.”

PAHT’s vision is to be one of the most digitally advanced Trusts in the UK by 2030. As a part of this transformation to drive improved patient care, the Trust has adopted technologies at the cutting edge of innovation. This includes a new electronic health record (EHR) system, a virtual holographic receptionist, Amazon-style lockers, and cloud telephony. With this proliferation of connected physical and virtual assets, the organization’s attack surface continues to significantly expand at a rapid pace and is protected by Armis.

“We are incredibly proud to support PAHT, enabling their security team to effectively balance innovation and security in pursuit of their larger goals,” said Mohammad Waqas, CTO, Healthcare at Armis. “As part of our critical infrastructure, healthcare is a top target of cybercriminals. It’s essential that we take action to proactively improve our defenses and that we stay steps ahead of bad actors with comprehensive security programs to ensure uninterrupted, world-class patient care.”

PAHT provides a full range of general acute, outpatient and diagnostic services, with 420 acute beds and operations that span three hospitals and a central administration center. The organization employs over 4,000 staff and serves a local population of approximately 350,000 people; with 500,000 additional individuals residing in the boundaries of the wider community within its extended catchment area.

Learn more about the results of Armis and PAHT’s partnership here.

Find more information about Armis’ work supporting global healthcare organizations here.

About Armis

Armis, the cyber exposure management & security company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250219747070/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teamily AI Reports 32× Quarterly User Growth, Positive Gross Margins, and Strong Global Adoption of Human–Agent Collaboration3.11.2026 14:00:00 CET | Press release

The AI-native collaboration platform reaches 320,000 users across 100+ countries, validates product-led growth and monetization, and prepares to expand its global AI agent ecosystem. Teamily AI, a human–agent collaboration platform that enables people and AI agents to work together in a unified, context-aware workspace, today announced significant growth and commercial milestones following a quarter of rapid global expansion. The company grew from 10,000 to 320,000 sign-ups in a single quarter, a 32× increase that works out to a compound monthly growth rate of 217.5%, just three months after its public launch in July 2026. With positive gross margins on paying users, and growing adoption among professional teams and businesses, Teamily AI establishes a foundation for scalable product-led growth (PLG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103047955/en/ 32× Global Growth in One Quarter Teamily AI grew from 10,000

Fourthline and Veridas Complete Merger to Create a European Leader in Bank-Grade Digital Identity3.11.2026 13:40:00 CET | Press release

One provider for identity, compliance and fraud prevention across 50+ countries, with a single integrated platform. Fourthline and Veridas combined will create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US; on track for 200 million verifications in 2026. With a projected combined revenue of more than €50m in 2026 and both businesses EBITDA-positive at closing, the company expects to reach €85m annual recurring revenue in 2029. Financials: The transaction includes funding of up to €65m provided by existing shareholder Finch Capital, new equity investment from Seaya Andromeda and debt financing from Ashgrove Capital. Fourthline and Veridas today announce the completion of their merger, first announced on 16 July 2026. The transaction closed on 3 November 2026 following the satisfaction of all closing conditions. This press release features multimedia. View the full rele

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 12:30:00 CET | Press release

Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment

Vedanta Limited Delivers Highest-ever Half-yearly Profit of $1.21 bn, up 151% YoY3.11.2026 12:26:00 CET | Press release

Indian multinational Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals and critical minerals, announced its consolidated results for the second quarter and half year ended 30 September 2026, delivering its best-ever financial performance driven by operational excellence and disciplined execution. Vedanta Limited achieved its highest-ever quarterly Profit of $649 mn, up 151% YoY, while half-yearly Profit reached a record $1.21 bn, up 151% YoY. Vedanta also declared its first interim dividend of INR 5 per share during the quarter, reinforcing its commitment to shareholder returns. The Company delivered record quarterly revenue of $2.70 bn, up 57% YoY, taking half-yearly revenue to a record $5.18 bn, up 54% YoY. Quarterly EBITDA surged 106% YoY to $1.04 bn, while half-yearly EBITDA reached a record $1.94 bn, up 103% YoY. EBITDA margins expanded to 60% in Q2 and 58% in H1, improving by 1,055 bps and 1,023 bps YoY, respectively. Vedanta further strengthened its balance sh

BeOne Medicines to Present at the Jefferies Global Healthcare Conference3.11.2026 12:01:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye